الصفحة الرئيسية>>Signaling Pathways>> Others>> Transcription Factors>>2-(1,8-Naphthyridin-2-yl)phenol

2-(1,8-Naphthyridin-2-yl)phenol (Synonyms: 2-NP)

رقم الكتالوجGC46503

2- (1،8-Naphthyridin-2-yl) الفينول هو محسن انتقائي لنسخ STAT1. 2- (1،8-Naphthyridin-2-yl) الفينول يمكن أن يعزز قدرة IFN-γ ؛ لمنع تكاثر سرطان الثدي وخلايا الساركوما الليفية البشرية.

Products are for research use only. Not for human use. We do not sell to patients.

2-(1,8-Naphthyridin-2-yl)phenol التركيب الكيميائي

Cas No.: 65182-56-1

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
71٫00
متوفر
5mg
65٫00
متوفر
10mg
111٫00
متوفر
25mg
222٫00
متوفر
50mg
352٫00
متوفر
100mg
565٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

 2-(1,8-Naphthyridin-2-yl)phenol (2-NP) is an enhancer of STAT1 activity.1 It enhances IFN-γ-induced STAT1-dependent signaling, but not IFN-γ-induced STAT3-dependent signaling or TNF-α-induced NF-κB-dependent signaling in cell-based reporter assays when used at a concentration of 45 µM. 2-NP (45 µM) increases IFN-γ-induced expression of the STAT1 target gene IRF3 and STAT1 phosphorylation in NIH3T3 cells. It increases growth inhibition of MCF-7 and 2fTGH cancer cells induced by IFN-γ at the same concentration.

1.Lynch, R.A., Etchin, J., Battle, T.E., et al.A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-γ in human cancer cellsCancer Res.67(3)1254-1261(2007)

مراجعات

Review for 2-(1,8-Naphthyridin-2-yl)phenol

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 2-(1,8-Naphthyridin-2-yl)phenol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.